Synonyms: SSR-125543A | SSR125543
Compound class:
Synthetic organic
Comment: Crinecerfont (SSR125543A) is a corticotropin releasing factor-1 (CRF-1) receptor antagonist.
![]() Ligand Activity Visualisation ChartsThese are box plot that provide a unique visualisation, summarising all the activity data for a ligand taken from ChEMBL and GtoPdb across multiple targets and species. Click on a plot to see the median, interquartile range, low and high data points. A value of zero indicates that no data are available. A separate chart is created for each target, and where possible the algorithm tries to merge ChEMBL and GtoPdb targets by matching them on name and UniProt accession, for each available species. However, please note that inconsistency in naming of targets may lead to data for the same target being reported across multiple charts. ✖ |
|
References |
1. Auchus RJ, Hamidi O, Pivonello R, Bancos I, Russo G, Witchel SF, Isidori AM, Rodien P, Srirangalingam U, Kiefer FW et al.. (2024)
Phase 3 Trial of Crinecerfont in Adult Congenital Adrenal Hyperplasia. NEJM, [Epub ahead of print]. DOI: 10.1056/NEJMoa2404656 |
2. Auchus RJ, Sarafoglou K, Fechner PY, Vogiatzi MG, Imel EA, Davis SM, Giri N, Sturgeon J, Roberts E, Chan JL et al.. (2022)
Crinecerfont Lowers Elevated Hormone Markers in Adults With 21-Hydroxylase Deficiency Congenital Adrenal Hyperplasia. J Clin Endocrinol Metab, 107 (3): 801-812. [PMID:34653252] |
3. Gully D, Geslin M, Serva L, Fontaine E, Roger P, Lair C, Darre V, Marcy C, Rouby PE, Simiand J et al.. (2002)
4-(2-Chloro-4-methoxy-5-methylphenyl)-N-[(1S)-2-cyclopropyl-1-(3-fluoro-4-methylphenyl)ethyl]5-methyl-N-(2-propynyl)-1,3-thiazol-2-amine hydrochloride (SSR125543A): a potent and selective corticotrophin-releasing factor(1) receptor antagonist. I. Biochemical and pharmacological characterization. J Pharmacol Exp Ther, 301 (1): 322-32. [PMID:11907190] |
4. Sarafoglou K, Kim MS, Lodish M, Felner EI, Martinerie L, Nokoff NJ, Clemente M, Fechner PY, Vogiatzi MG, Speiser PW et al.. (2024)
Phase 3 Trial of Crinecerfont in Pediatric Congenital Adrenal Hyperplasia. NEJM, [Epub ahead of print]. DOI: 10.1056/NEJMoa240465 |